<DOC>
	<DOCNO>NCT01685008</DOCNO>
	<brief_summary>This open-label , multicentre study characterize safety preliminary efficacy human anti CD19 antibody MOR00208 adult subject relapsed/refractory non-Hodgkin´s lymphoma ( NHL ) receive least 1 prior therapy contain rituximab ( least ) .</brief_summary>
	<brief_title>Study Fc-Optimized Anti-CD19 Antibody ( MOR00208 ) Treat Non-Hodgkin´s Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1. male female patient ≥ 18 year age . 2. histologicallyconfirmed diagnosis accord REAL/WHO classification , follow Bcell lymphoma : 1 . FL 2 . MCL 3 . DLBCL 4 . Other indolent NHL ( eg , MZL/MALT ) 3 . Patients ' NHL must progress least 1 prior rituximab contain regimen . 4. one site measurable disease magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan define least one lesion measure least 1.5 × 1.5 cm , Exception : For patient MCL , patient nonmeasurable disease evaluable site ( bone marrow , spleen , peripheral blood , gastrointestinal tract ) enrol . 5 . Patients previously receive autologous stem cell transplantation must least 4 week posttransplant study drug administration must exhibit full haematological recovery 6. discontinue previous monoclonal antibody therapy ( except rituximab ) radioimmunotherapy administration least 60 day study drug administration . 7. rituximab least 14 day screen visit confirm either response disease progression rituximab treatment . 8 . Patients DLBCL positive [ 18F ] fluorodeoxyglucosepositron emission tomography ( FDGPET ) scan baseline ( Cheson response criterion ) 9 . Life expectancy &gt; 3 month . 10 . ECOG performance status &lt; 3 . 11. laboratory criterion screen : 1 . Absolute neutrophil count ( ANC ) ≥ 1.0 ( 1000/mm3 ) 2 . Platelet count ≥ 75 × 109/L without previous transfusion within 10 day first study drug administration 3 . Haemoglobin ≥ 8.0 g/dL ( may transfuse ) 4 . Serum creatinine &lt; 2.0 x upper limit normal ( ULN ) 5 . Total bilirubin ≤ 2.0 × ULN 6 . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 × ULN . 12 . If female childbearing potential , negative pregnancy test must confirm enrolment use doublebarrier contraception , oral contraceptive plus barrier contraceptive , confirmation undergone clinically document total hysterectomy and/or oophorectomy , tubal ligation . 13 . If male , effective barrier method contraception must use study 3 month last dose patient sexually active female childbearing potential . 14. able comply studyrelated procedure , medication use , evaluation . 15. able understand give write informed consent comply study protocol . 1 . Previous treatment cytotoxic chemotherapy , immunotherapy , radiotherapy lymphoma specific therapy within 14 day screen visit patient recover side effect previous lymphomaspecific therapy . 2 . Treatment systemic investigational agent within 28 day screen visit . 3 . Previous treatment antiCD19 antibody fragment 4 . Previous allogenic stem cell transplantation . 5 . Known suspected hypersensitivity excipients contain study drug formulation . 6 . Clinically significant cardiovascular disease cardiac insufficiency , cardiomyopathy , preexist clinically significant arrhythmia , acute myocardial infarction within 3 month enrolment , angina pectoris within 3 month enrolment . 7 . Clinical laboratory evidence active hepatitis B hepatitis C 8 . History HIV infection . 9 . Any active systemic infection ( viral , fungal , bacterial ) require active parenteral antibiotic therapy within 4 week study drug administration . 10 . Current treatment immunosuppressive agent prescribe corticosteroid ( 10mg prednisone equivalent ) . 11 . Major surgery radiation therapy within 4 week first study drug administration . 12 . Systemic disease ( cardiovascular , renal , hepatic , etc ) would prevent study treatment investigator 's opinion . 13 . History clinical evidence central nervous system ( CNS ) , meningeal , epidural disease , include brain metastasis . 14 . Active treatment/chemotherapy another primary malignancy within past 5 year 15 . Pregnancy breastfeed woman woman childbearing potential use acceptable method birth control . 16 . History noncompliance medical regimen patient consider potentially unreliable cooperative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>NHL</keyword>
	<keyword>CD19</keyword>
	<keyword>MOR208</keyword>
	<keyword>MOR00208</keyword>
	<keyword>Xmab5574</keyword>
	<keyword>B-Cell Non-Hodgkin´s Lymphoma</keyword>
	<keyword>Fc-optimized Anti-CD19 Antibody</keyword>
</DOC>